痛风降尿酸治疗试验核心域报告与测量时机的共识推荐:一项德尔菲研究
该德尔菲研究旨在就OMERACT认可的「慢性」痛风试验核心域在3期或以后降尿酸治疗试验中的报告方式和测量时机达成共识。患者研究伙伴和其他利益相关者完成三轮调查,共识定义为两组中≥70%参与者对某条目评分为7-9分。结果显示所有七个核心域均有多个报告条目达成共识,基线和最终访视对所有核心域达成共识,血清尿酸在≤6个月试验中每月测量、在>6至≤12个月试验中每3个月测量达成共识。
要点
- 所有七个核心域均有多个报告条目达成共识,血清尿酸推荐报告达标比例、均值及均值变化。
- 基线和最终访视的测量时点对所有七个核心域均达成共识。
- 血清尿酸在≤6个月试验中每月测量、在>6至≤12个月试验中每3个月测量达成共识。
核心结论
- 这些关于如何以及何时报告OMERACT认可核心域的推荐填补了当前核心结局集的空白,采用后应提高痛风试验的一致性和可比性。
研究设计与样本
- 采用三轮德尔菲调查,由患者研究伙伴和其他利益相关者两组参与,对七个核心域的报告方式和测量时机进行1-9评分,共识定义为两组中≥70%参与者评分为7-9分。
主要发现
- 对于「核心域应如何报告」,所有七个核心域均有超过一个条目达成共识。
- 对于血清尿酸,三个条目达成共识:达到预设目标血清尿酸的患者比例、平均血清尿酸和平均血清尿酸变化。
- 对于测量频率问题,基线和最终访视时点对所有七个核心域均达成共识。
- 对于血清尿酸,在≤6个月试验中每月频率达成共识,在>6至≤12个月试验中每3个月频率达成共识。
关键数值与推荐
- 共识定义为两组中≥70%参与者对某条目评分为7-9分(1=不重要,9=关键)。
- 血清尿酸报告条目共识:达到预设目标血清尿酸的患者比例、平均血清尿酸、平均血清尿酸变化。
- 血清尿酸测量频率共识:≤6个月试验中每月一次,>6至≤12个月试验中每3个月一次。
- 所有七个核心域的测量时点共识:基线和最终访视。
临床怎么用
- 在3期或以后痛风降尿酸治疗试验中,按共识推荐报告七个核心域,并至少在基线和最终访视测量。
- 血清尿酸报告应包含达标比例、均值和均值变化,测量频率按试验时长选择每月或每3个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To achieve consensus for how the Outcome Measures in Rheumatology (OMERACT) endorsed core domains for "chronic" gout trials should be reported, as well as when they should be measured and reported, in phase 3 or later urate-lowering therapy trials. METHODS: Three rounds of a Delphi survey were completed by two groups: patient research partners and other interest holders. For each of the seven core domains there were two questions: "How should the domain be reported?" and "When should the domain be measured and reported?". The measurement timing question was repeated for two trial durations: '≤6 months duration' and '>6 to ≤12 months duration'. Participants scored items 1-9 (1=not important, 9=critical) Consensus was defined as ≥70% participants from both groups scoring an item 7-9. RESULTS: For "How should the core domain be reported?", all seven core domains had more than one item reach consensus. For serum urate, three items met consensus: 'proportion of patients achieving a pre-specified target serum urate', 'mean serum urate' and 'mean change in serum urate'. For the measurement frequency question, the 'baseline' and 'final visit' time points reached consensus for all seven core domains. For serum urate, the 'monthly' frequency in trials ≤6 months duration and the '3-monthly' frequency in trials >6 to ≤12 months duration reached consensus. CONCLUSION: These recommendations on how and when to report the OMERACT-endorsed core domains in urate-lowering therapy trials address a gap in the current core outcome sets. Adoption of these recommendations should improve consistency and comparability across gout trials.
引用
- Prendergast E, Dalbeth N, Christensen R, et al. Consensus recommendations for optimal trial design and reporting of core domains in urate-lowering therapy trials for gout: A Delphi study. Semin Arthritis Rheum. 2026. PMID: 42785113. doi:10.1016/j.semarthrit.2026.153079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。